Cytokinetics 5022: A Phase 2, Multi-center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CK-2127107 in Patients with Amyotrophic Lateral Sclerosis (ALS)

July 26, 2018
https://clinicaltrials.gov/ct2/show/NCT03160898
Amyotrophic Lateral Sclerosis ALS
Principal Investigator: Daniel S Newman, MD
ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
Accepting Participants